Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats obsessions and compulsions. Sold as Anafranil. Every FDA application for this active ingredient: 1 branded and 21 generic.
As of Nov 16, 2026, FDA lists 22 applications for Clomipramine Hydrochloride (sold as Anafranil), first approved Dec 29, 1989, with 0 new uses approved and 0 published complete response letters.
First approved: Dec 29, 1989
Applications: 22
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $13.8M
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Clomipramine HCl
Part D
$12.8M
-10%
16,558
Anafranil
Part D
$982K
-5%
36
Medicaid Spending
What state Medicaid programs paid pharmacies in 2025, before rebates, by product name; see every drug
Clomipramine
$2.6M for 74,995 prescriptions, -10% on 2024
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
Clomipramine 25 mg capsule: $0.203 per unitGeneric · -22% in a year
Clomipramine 50 mg capsule: $0.252 per unitGeneric · -9% in a year
Clomipramine 75 mg capsule: $0.270 per unitGeneric · -30% in a year
Adverse Event Reports (FAERS)
Cases reported to FDA naming this drug as the primary suspect, 2025 Q4 to 2026 Q3. A report does not show the drug caused the event.
AnafranilDrugs with a new additional indication and a new dosage for the treatment of cataplexy associated with narcolepsy. · Alfresa Pharma Corporation · Nov 22, 2013
Clinical Trials
4 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA